BDRX Latest News, Press Relases and Analysis

All

Press Releases

8 days ago - By: Chartmill - Mentions: VNDA ENR UUU GSM ...

Let's uncover which stocks are experiencing notable gaps during today's session.

2 days ago - By: Biodexa Pharmaceuticals PLC

Biodexa Activates First European Site for Registrational Phase 3 Serenta Trial in FAP

8 days ago - By: Benzinga - Mentions: ZYXI ITRM ARVN OLMA ...

12 Health Care Stocks Moving In Tuesday's Intraday Session

8 days ago - By: Benzinga - Mentions: CANF IFRX ARVN OLMA ...

12 Health Care Stocks Moving In Tuesday's Pre-Market Session

23 days ago - By: Biodexa Pharmaceuticals PLC

Biodexa Announces Approval of CTA in Europe for Phase 3 Serenta Trial in FAP First European patient expected to be enrolled in 4Q 2025 Addressable US - European Market Put at $7 Billion

2 months ago - By: Biodexa Pharmaceuticals PLC

Biodexa to Host Breakfast Symposium on FAP Mechanisms and Chemoprevention Trial Issues at CGA – IGC Conference on October 11, 2025

3 months ago - By: Biodexa Pharmaceuticals PLC

Interim results for the six months ended June 30, 2025

3 months ago - By: ACCESS Newswire

Biodexa Moves Into Phase 3 With eRapa For FAP With First Patients Enrolled

3 months ago - By: Zacks Investment Research

Biodexa Pharmaceuticals PLC Unsponsored ADR (BDRX) Upgraded to Buy: What Does It Mean for the Stock?

3 months ago - By: Biodexa Pharmaceuticals PLC

Biodexa Announces Enrolment of First Patients into Pivotal Phase 3 Serenta Trial in Familial Adenomatous Polyposis (FAP)

4 months ago - By: Biodexa Pharmaceuticals PLC

ADR Ratio Change Effective

4 months ago - By: ACCESS Newswire

How Biodexa Is Racing To Get Its Phase 3 Program in FAP Under Way And Gain First-Mover Advantage in a $7Bn Addressable Market

4 months ago - By: Biodexa Pharmaceuticals PLC

ADR Ratio Change

5 months ago - By: Biodexa Pharmaceuticals PLC

Biodexa Announces Filing of CTA in Europe for Phase 3 Serenta Trial in Familial Adenomatous Polyposis (FAP)

5 months ago - By: Biodexa Pharmaceuticals PLC

Results of Annual General Meeting

5 months ago - By: Biodexa Pharmaceuticals PLC

Biodexa Announces Activation of First Clinical Study Site for Phase 3 Serenta Trial in Familial Adenomatous Polyposis (FAP)

5 months ago - By: Biodexa Pharmaceuticals PLC

Biodexa Unveils "Serenta" as the Name of its Upcoming Phase 3 Study In Familial Adenomatous Polyposis (FAP)

5 months ago - By: ACCESS Newswire

Biodexa Hits Key Milestone For Its Type 1 Diabetes Candidate Tolimidone, Enrolls First Patient In Phase 2a Study

6 months ago - By: Biodexa Pharmaceuticals PLC

Result of General Meeting

6 months ago - By: Biodexa Pharmaceuticals PLC

Biodexa Announces Recruitment of First Patient in Phase 2 Study of Tolimidone in Type 1 Diabetes

6 months ago - By: Yahoo Finance - Mentions: RY RY.CA SEDG PATH ...

UiPath price target raised to $15 from $12 at TD Cowen

6 months ago - By: Yahoo Finance - Mentions: HRI HEES PD PATH ...

Herc Holdings, H&E Equipment announce expiration of tender offer

6 months ago - By: Yahoo Finance - Mentions: BLRX SEDG PD WETO ...

BioLineRx upgraded to Buy from Hold at JonesResearch

6 months ago - By: Yahoo Finance - Mentions: RY RY.CA SPWR PD ...

PagerDuty price target lowered to $17 from $18 at TD Cowen

6 months ago - By: Yahoo Finance - Mentions: RY RY.CA ULTA ZS ...

Zscaler price target raised to $290 from $245 at Evercore ISI

6 months ago - By: Yahoo Finance - Mentions: DHI CMG

Biodexa Pharmaceuticals sees cash runway into 1Q26

6 months ago - By: Yahoo Finance - Mentions: LMT JPM SEDG LHX ...

L3Harris Technologies price target raised to $270 from $240 at TD Cowen

6 months ago - By: Biodexa Pharmaceuticals PLC

BIODEXA PHARMACEUTICALS-ADR (BDRX) Stock News

BDRX Latest News, Press Relases and Analysis

Let's uncover which stocks are experiencing notable gaps during today's session.

Biodexa Activates First European Site for Registrational Phase 3 Serenta Trial in FAP

12 Health Care Stocks Moving In Tuesday's Intraday Session

12 Health Care Stocks Moving In Tuesday's Pre-Market Session

Biodexa Announces Approval of CTA in Europe for Phase 3 Serenta Trial in FAP First European patient expected to be enrolled in 4Q 2025 Addressable US - European Market Put at $7 Billion

Biodexa to Host Breakfast Symposium on FAP Mechanisms and Chemoprevention Trial Issues at CGA – IGC Conference on October 11, 2025

Interim results for the six months ended June 30, 2025

Biodexa Moves Into Phase 3 With eRapa For FAP With First Patients Enrolled

Biodexa Pharmaceuticals PLC Unsponsored ADR (BDRX) Upgraded to Buy: What Does It Mean for the Stock?

Biodexa Announces Enrolment of First Patients into Pivotal Phase 3 Serenta Trial in Familial Adenomatous Polyposis (FAP)

ADR Ratio Change Effective

How Biodexa Is Racing To Get Its Phase 3 Program in FAP Under Way And Gain First-Mover Advantage in a $7Bn Addressable Market

ADR Ratio Change

Biodexa Announces Filing of CTA in Europe for Phase 3 Serenta Trial in Familial Adenomatous Polyposis (FAP)

Results of Annual General Meeting

Biodexa Announces Activation of First Clinical Study Site for Phase 3 Serenta Trial in Familial Adenomatous Polyposis (FAP)

Biodexa Unveils "Serenta" as the Name of its Upcoming Phase 3 Study In Familial Adenomatous Polyposis (FAP)

Biodexa Hits Key Milestone For Its Type 1 Diabetes Candidate Tolimidone, Enrolls First Patient In Phase 2a Study

Result of General Meeting

Biodexa Announces Recruitment of First Patient in Phase 2 Study of Tolimidone in Type 1 Diabetes

UiPath price target raised to $15 from $12 at TD Cowen

Herc Holdings, H&E Equipment announce expiration of tender offer

BioLineRx upgraded to Buy from Hold at JonesResearch

PagerDuty price target lowered to $17 from $18 at TD Cowen

Zscaler price target raised to $290 from $245 at Evercore ISI

Biodexa Pharmaceuticals sees cash runway into 1Q26

L3Harris Technologies price target raised to $270 from $240 at TD Cowen

Shareholder Update